» Articles » PMID: 21672193

Systematic Review with Meta-analysis of the Epidemiological Evidence Relating Smoking to COPD, Chronic Bronchitis and Emphysema

Overview
Journal BMC Pulm Med
Publisher Biomed Central
Specialty Pulmonary Medicine
Date 2011 Jun 16
PMID 21672193
Citations 150
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Smoking is a known cause of the outcomes COPD, chronic bronchitis (CB) and emphysema, but no previous systematic review exists. We summarize evidence for various smoking indices.

Methods: Based on MEDLINE searches and other sources we obtained papers published to 2006 describing epidemiological studies relating incidence or prevalence of these outcomes to smoking. Studies in children or adolescents, or in populations at high respiratory disease risk or with co-existing diseases were excluded. Study-specific data were extracted on design, exposures and outcomes considered, and confounder adjustment. For each outcome RRs/ORs and 95% CIs were extracted for ever, current and ex smoking and various dose response indices, and meta-analyses and meta-regressions conducted to determine how relationships were modified by various study and RR characteristics.

Results: Of 218 studies identified, 133 provide data for COPD, 101 for CB and 28 for emphysema. RR estimates are markedly heterogeneous. Based on random-effects meta-analyses of most-adjusted RR/ORs, estimates are elevated for ever smoking (COPD 2.89, CI 2.63-3.17, n = 129 RRs; CB 2.69, 2.50-2.90, n = 114; emphysema 4.51, 3.38-6.02, n = 28), current smoking (COPD 3.51, 3.08-3.99; CB 3.41, 3.13-3.72; emphysema 4.87, 2.83-8.41) and ex smoking (COPD 2.35, 2.11-2.63; CB 1.63, 1.50-1.78; emphysema 3.52, 2.51-4.94). For COPD, RRs are higher for males, for studies conducted in North America, for cigarette smoking rather than any product smoking, and where the unexposed base is never smoking any product, and are markedly lower when asthma is included in the COPD definition. Variations by sex, continent, smoking product and unexposed group are in the same direction for CB, but less clearly demonstrated. For all outcomes RRs are higher when based on mortality, and for COPD are markedly lower when based on lung function. For all outcomes, risk increases with amount smoked and pack-years. Limited data show risk decreases with increasing starting age for COPD and CB and with increasing quitting duration for COPD. No clear relationship is seen with duration of smoking.

Conclusions: The results confirm and quantify the causal relationships with smoking.

Citing Articles

Respiratory rate and its associations with disease and lifestyle factors in the general population - results from the KORA-FF4 study.

Ruckert-Eheberg I, Steger A, Muller A, Linkohr B, Barthel P, Maier M PLoS One. 2025; 20(3):e0318502.

PMID: 40067853 PMC: 11896064. DOI: 10.1371/journal.pone.0318502.


Outcomes of metabolic syndrome and anxiety levels in light and heavy smokers.

Sahin M, Yuzugullu D PeerJ. 2025; 13:e19069.

PMID: 40061234 PMC: 11890032. DOI: 10.7717/peerj.19069.


Implementing a smoke-free generation policy for Canada: estimates of the long-term impacts.

Coyle D Health Promot Chronic Dis Prev Can. 2025; 45(1):39-53.

PMID: 39817710 PMC: 11785163. DOI: 10.24095/hpcdp.45.1.03.


Gastrointestinal cancer incidence after lung transplantation in sarcoidosis patients.

Saeed G, Sanders T, Tumin D, Obi O, Oghoghorie S, Ali H Ann Gastroenterol. 2025; 38(1):80-84.

PMID: 39802287 PMC: 11724385. DOI: 10.20524/aog.2024.0932.


Public support for new tobacco control measures in Poland: A cross-sectional survey 2024.

Grudziaz-Sekowska J, Sekowski K, Grzesczyk-Nojszewska Z, Sierpinski R, Ostrowski J, Pinkas J Tob Prev Cessat. 2024; 10.

PMID: 39735216 PMC: 11671779. DOI: 10.18332/tpc/196135.


References
1.
Pauwels R, Buist A, Calverley P, Jenkins C, Hurd S . Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med. 2001; 163(5):1256-76. DOI: 10.1164/ajrccm.163.5.2101039. View

2.
Tsushima K, Sone S, Yoshikawa S, Furuya S, Yasuo M, Suzuki T . Clinical differences in the Global Initiative for Chronic Obstructive Lung Disease Stage 0. Respir Med. 2006; 100(8):1360-7. DOI: 10.1016/j.rmed.2005.11.021. View

3.
DerSimonian R, Laird N . Meta-analysis in clinical trials. Control Clin Trials. 1986; 7(3):177-88. DOI: 10.1016/0197-2456(86)90046-2. View

4.
Camilli A, Burrows B, KNUDSON R, Lyle S, LEBOWITZ M . Longitudinal changes in forced expiratory volume in one second in adults. Effects of smoking and smoking cessation. Am Rev Respir Dis. 1987; 135(4):794-9. DOI: 10.1164/arrd.1987.135.4.794. View

5.
Chen Z, Xu Z, Collins R, Li W, Peto R . Early health effects of the emerging tobacco epidemic in China. A 16-year prospective study. JAMA. 1997; 278(18):1500-4. DOI: 10.1001/jama.278.18.1500. View